Published in Medical Letter on the CDC and FDA, August 23rd, 2009
ATryn is not indicated for treatment of thromboembolic events in HD AT patients. Additionally, data validate dosing algorithms that, along with AT activity monitoring, allows physicians to normalize antithrombin levels during the high-risk situations of surgery and childbirth.
"ATryn provides physicians with a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA